![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HD Lighthouse Contributing Editor's Comment:
An exciting new robotic microscope has ended the controversy over the role of the aggregates of mutant protein that are found in the brains of HD patients as well as the HD mice. The aggregates do not cause cell death. This information is good to know because research resources can be redirected away from finding ways to dissolve the aggregates and toward more promising avenues. Even more important, however, is the potential for developing an accurate model of the disease process. Right now, we know a lot about what goes wrong with neurons in Huntington's Disease and there's a long list. Strategies for treatment involve creating a cocktail of drugs and supplements to address those problems in the short term as well as finding a safe way to turn off the HD gene within the next five or ten years. If researchers can pinpoint exactly what first goes wrong in the neuron so that the cells can no longer cope with the HD protein, it might be possible to stop HD by coming up with a therapy to aimed at that turning point.
Gladstone researchers resolve key Huntington's disease mystery in Nature cover storyAs reported in the cover story in the current issue of Nature (Oct. 14, 2004), the team determined that abnormal deposits of mutant huntingtin protein, which appear in the brains of all Huntington's disease patients, aren't the cause of neuronal death. Scientists know that mutant huntingtin protein is responsible for the disease, but they have not known in what form it wreaks its havoc. They haven't known, for instance, whether the abnormal deposits of the protein, known as "inclusion bodies," were, themselves, causative, protective or incidental to the disease. In the current study, the Gladstone team determined that inclusion bodies are a beneficial coping response, possibly sequestering mutant huntingtin protein, thereby reducing levels of the protein elsewhere in the neuron, and thus prolonging neurons' survival. The finding suggests that mutant huntingtin protein inflicts its damage in some form other than as inclusion bodies, which are insoluble, or resistant to being dissolved in liquid. Investigators may now focus attention on the possibility that the real culprit is a more soluble form of mutant huntingtin spread throughout the neuron, or nerve cell, among other theories. "We are very excited by these results," says lead investigator Steven Finkbeiner, MD, PhD, an assistant investigator at the Gladstone Institute of Neurological Disease and assistant professor of neurology and physiology at University of California, San Francisco (UCSF). "They will help us to better focus efforts to identify the mechanisms by which the huntingtin protein causes Huntington's and may add to the understanding of other neurodegenerative disorders." Traditionally, scientists have tried to illuminate the role of the mutant protein within neurons by taking one-time snapshots of individual cells, a slow process that doesn't allow researchers to track changes in any given cell over time. Beyond slowness, a fundamental problem with this conventional approach is that the snapshots are not only taken at different times but also each image is of a completely different population of cells than the other. Scientists have tried to use these images to piece together theories of disease progression, but have had great difficulty interpreting their results because of the lack of continuity between images. To address these issues, Finkbeiner developed an automated microscope that allows researchers to track changes in individual neurons over time, thus enabling them to identify factors that predict the fate of the cell. "With this new technology, we can examine neurons well before they die, make measurements of whatever we wish, and then determine which factors have prognostic value, whether they predict survival or neurodegeneration, and how strong the prediction is. This is a powerful new way to guide our investigation into the underlying mechanisms of neurodegeneration," he explains. In their study, the scientists introduced fluorescently tagged versions of huntingtin protein into neurons. They then used the robotic microscope to monitor the accumulation of the abnormal protein into inclusion bodies, as well as to monitor the levels of intracellular huntingtin protein, and the length of survival of thousands of individual cells over time. Sophisticated statistical techniques for survival analysis were then used to determine whether a particular abnormality predicted early death and might be pathogenic, or predicted longer survival and might be beneficial. The findings suggest, says Finkbeiner, that inclusion bodies lock up mutant huntingtin in other parts of a cell and keep it from interfering with the rest of the neuron in ways that can trigger cell death. These findings provide evidence that inclusion bodies in Huntington's disease, and possibly other neurodegenerative diseases, help neurons cope with toxic proteins and prevent neurodegeneration. The approach developed by the Finkbeiner group -- combining the use of a robotic microscope with powerful techniques of statistical analysis -- could also be used in studies of other neurodegenerative diseases characterized by the accumulation of cellular proteins, including Alzheimer's disease, prion diseases, amyotrophic lateral sclerosis (Lou Gehrig's disease), Parkinson's disease, and a group of nine so-called polyglutamine diseases of which Huntington's is the most widely known. Moreover, the approach could be used to measure the nature and magnitude of the relationship between any two biological events within a cell that are separated by time. With this tool, researchers can begin to answer such fundamental questions as:
* Is there a relationship at all, or are the two events simply coincidental? These are questions that recur in all aspects of cell biology. As Professor Harry T. Orr of the University of Minnesota explains in a companion Nature commentary, "In the long term, strength of this study lies in the approach itself. The capability to determine if a cellular feature of a disease is pathogenic, beneficial or merely incidental to a disease process will be of considerable advantage for understanding disease mechanisms. Will the results reported here end the debate on the pathogenic role of inclusion bodies in the polyglutamine diseases? If not, one wonders what would." Huntington's disease is a hereditary, progressive neurodegenerative disorder characterized by the development of emotional, behavioral, and psychiatric abnormalities, loss of intellectual and cognitive functioning, and motor disturbances. Although symptoms typically become evident during the fourth or fifth decades of life, the age at onset is variable and ranges from early childhood to the 70s or 80s. It's named for the American physician who initially described the condition in 1872. The paper, "Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death," was co-authored by Finkbeiner and fellow GIND staff members Montserrat Arrasate and Siddhartha Mitra; Erik S. Schweitzer of the Brain Research Institute, UCLA; and Mark R. Segal of the Division of Biostatistics, UCSF. Primary support for this work was provided by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). Additional support was provided by the National Institute of Aging within the NIH, and the J. David Gladstone Institutes. To read Dr. Finkbeiner's account of the research: http://www.gladstone.ucsf.edu/gladstone/php/section.php?sitename=focus&id=1280 Tracked on the Lighthouse:
Source: press release
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
26 Sep 2007
Press release for the BDNF neurogenesis study.
25 Aug 2007
Gene Expression Analysis and Extra-Mitochondrial Energy Metabolism
The HD protein causes a depletion in cellular energy but not through direct effects on the mitochondria, the cell's energy factory.
24 Aug 2007
RE1/NRSE Mediated Gene Transcription
Exciting research suggests that restoring the expression of the genes that the HD protein suppresses could be a major treatment.
20 Aug 2007
The Molecular Zip Code Research Yields a Drug Target
The molecular zip code research suggests that a kinase inhibitor could be a major treatment for Huntington
19 May 2007
D1 receptors and HD
Researchers generated a mouse which progressively lost Dopamine 1 receptor cells and got Huntington's Disease like symptoms.
1 Apr 2007
Copper in the HD brain
Researchers have discovered that excess copper plays a role in Huntington's Disease pathology.
13 Feb 2007
Molecular Zipcodes Provide Address for HD Protein
New findings based on new technology show that the HD protein is being misdirected within the cell. Small molecules are being developed which might place a 'molecular zip code' on the problem.
6 Feb 2007
NCAMs in the HD mice
Problems with NCAMs may explain cognitive and olfactory dysfunction in HD.
19 Dec 2006
Stem Cells and The Aging Brain
Stem cells are still present in the middle aged brain; they just aren't dividing.
8 Dec 2006
ReNeuron Files Application with FDA to Begin Phase I Study of Stem Cell Treatment for Stroke Patients.
A company currently doing stem cell research in animal models of HD, has filed an application with the FDA for permission to begin clinical trials of stem cell treatments for stroke victims.
All Updates for The Brain | |||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|